首页> 外文期刊>Nature Communications >TCF12 is mutated in anaplastic oligodendroglioma
【24h】

TCF12 is mutated in anaplastic oligodendroglioma

机译:TCF12在间变性少突胶质细胞瘤中发生突变

获取原文
获取原文并翻译 | 示例
           

摘要

Anaplastic oligodendroglioma (AO) are rare primary brain tumours that are generally incurable, with heterogeneous prognosis and few treatment targets identified. Most oligodendrogliomas have chromosomes 1p/19q co-deletion and an IDH mutation. Here we analysed 51 AO by whole-exome sequencing, identifying previously reported frequent somatic mutations in CIC and FUBP1. We also identified recurrent mutations in TCF12 and in an additional series of 83 AO. Overall, 7.5% of AO are mutated for TCF12, which encodes an oligodendrocyte-related transcription factor. Eighty percent of TCF12 mutations identified were in either the bHLH domain, which is important for TCF12 function as a transcription factor, or were frameshift mutations leading to TCF12 truncated for this domain. We show that these mutations compromise TCF12 transcriptional activity and are associated with a more aggressive tumour type. Our analysis provides further insights into the unique and shared pathways driving AO.
机译:间变性少突胶质细胞瘤(AO)是罕见的原发性脑部肿瘤,通常无法治愈,预后不均,很少确定治疗目标。大多数少突胶质细胞瘤具有1p / 19q共缺失染色体和IDH突变。在这里,我们通过全外显子组测序分析了51个AO,确定了先前报道的CIC和FUBP1的频繁体细胞突变。我们还确定了TCF12和其他系列的83 AO中的复发突变。总体而言,有7.5%的AO突变为TCF12,后者编码少突胶质细胞相关的转录因子。鉴定出的80%的TCF12突变位于bHLH域中,这对于TCF12作为转录因子起作用很重要,或者是移码突变导致该域的TCF12被截短。我们表明这些突变损害TCF12转录活性,并与更具侵略性的肿瘤类型相关联。我们的分析为驱动AO的独特共享途径提供了进一步的见解。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号